EQS-News Zur Rose Group signals dynamic revenue development in the first quarter of 2021
EQS Group-News: Zur Rose Group AG / Key word(s): Quarterly / Interim Statement
Zur Rose Group signals dynamic revenue development in the first quarter of 2021
- Sustained positive growth of 16.0 per cent
- Strong sales growth in Germany of 25.2 per cent
- Expansion of the DocMorris healthcare platform with new services
- Launch of www.docmorriscare.com/adipositas as strategic milestone
- Continuation of integration activities: Merger of apo-rot with DocMorris
The Zur Rose Group posted significant sales growth of 16.0 per cent in local currency terms in the first quarter of 2021, continuing along the growth path, even compared to the exceptionally strong previous year's quarter. In Group currency terms, revenue increased 17.8 per cent to CHF 502.7 million despite the decline in demand for flu and cold medication resulting from the tightened hygiene measures. The general move towards more online purchases and the continued positive trend in new clients contributed to the dynamic development. The number of active customers rose by more than 600,000 to 11.1 million in the last quarter.
Constant pleasing development in the segments
In Germany the Zur Rose Group grew significantly in the first quarter. Sales increased by 25.2 per cent in local currency terms and by 27.9 per cent in Group currency terms to CHF 337.2 million1. The online business in non-prescription drugs as well as beauty and personal care products was the driver of this positive development. The prescription drugs business was virtually at the same level as the previous year's quarter based on paper prescriptions and is testament to the high degree of customer loyalty.